Theoretical basis for the activity of thalidomide

BioDrugs

Volumn 15, Issue 10, 2001, Pages 681-703

  Meierhofer, Christian ^a   Dunzendorfer, Stefan ^a   Wiedermann, Christianj ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANTIBODY RESPONSE; BEHCET DISEASE; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; ENTERITIS; ERYTHEMA NODOSUM LEPROSUM; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE MIGRATION; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; SARCOIDOSIS; SOLID TUMOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; VIRUS REPLICATION;

EID: 0035166641     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200115100-00005     Document Type: Review

References (191)

1. Sands BE, Podolsky DK. New life in a sleeper: thalidomide and Crohn's disease [editorial]. Gastroenterology 1999; 117: 1485-8
2. Wenzel D, Wenzel KH. Der Contergan-Prozess, vol. 2. Berlin: Wissenschaft und Forschung GmbH, 1968: 56-70
3. Florence AL. Is thalidomide to blame? BMJ 1960: 1954
4. McBride WG. Thalidomide and congenital abnormalities [editorial]. Lancet 1961; II: 1358
5. Lenz W. Thalidomide and congenital abnormalities [editorial). Lancet 1962; I: 45
6. Lenz W. A short history of thalidomide embryopathy. Teratology 1988; 38; 203-15
7. Wiedemann HR. Hinweis auf eine derzeitige Häufung hypound aplastischer Fehlbildungen der Gliedmassen. Med Welt 1988; 37: 1863
8. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961: 1358
9. Thalidomide: potential benefits and risks: an open public scientific workshop. 1997 Sep 9-10; Bethesda, Maryland: Natcher Conference Center, National Institutes of Health
10. Zwingenberger K, Wnendt S. Immunomodulation by thalidomide: systemic review of the literature and unpublished observations. J Inflamm 1995-6; 46: 177-211
11. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965; 6: 303-6
12. Job CK, Jacobson RR, Hastings RC. Simultaneous upgrading reaction and erythema nodosum leprosum in a patient with lepromatous leprosy. Int J Lepr Other Mycobact Dis 1988; 56: 437-42
13. Sheskin J. The treatment of lepra reaction in lepromatous leprosy. Fifteen years' experience with thalidomide. Int J Dermatol 1980; 19: 318-22
14. Hellmann K, Duke DI, Tucker DF. Prolongation of skin homograft survival by thalidomide. BMJ 1965; 687-9
15. Turk JL, Hellman K, Duke DI. Effect of thalidomide on the immunological response in local lymph nodes after a skin homograft. Lancet 1966; 1 (7447): 1134-6
16. Vogelsang GB, Hess AD, Gordon G, et al. Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model. Transplantation 1986; 41: 644-7
17. Field EO, Gibbs JE, Tucker DF, et al. Effect of thalidomide on the graft versus host reaction. Nature 1966; 211: 1308-10
18. Cornea P, Vladutiu A, Marcovici G. The immuno-suppressive effect of thalidomide in experimental tuberculosis in guineapigs. Tubercle 1967; 48: 51-3
19. Moreira A, Wang J, Tsenova L, et al. The effect of thalidomide on the cellular immune response to mycobacteria infection in mice. J Cell Biochem 1995; 19B Suppl.: 88
20. van Crevel R, Vonk AG, Netea MG, et al. Modulation of LPS-, PHA- and M. tuberculosis-mediated cytokine production by pentoxifylline and thalidomide. Eur Cytokine Netw 2000; 11 : 574-9
21. Moreira AL, Tsenova-Berkova L, Wang J, et al. Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis. Tuber Lung Dis 1997; 78: 47-55
22. Yazici H, Yurdakul S, Hamuryudan V. Behcet disease. Curr OpinRheumatol2001; 13: 18-22
23. Baert FJ, Rutgeerts PJ. Medical therapies for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep 2000; 2:446-50
24. Muller-Quernheim J. Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J 1998; 12: 716-38
25. Khamashta MA, Ruiz-Irastorza G, Hughes GR. Therapy of systemic lupus erythematosus: new agents and new evidence. Expert Opin Invest Drugs 2000; 9: 1581-93
26. Ruiz-Irastorza G, Khamashta MA, Castellino G, et al. Systemic lupus erythematosus. Lancet 2001; 357: 1027-32
27. Winter W, Frankus E. Thalidomide enantiomers. Lancet 1992; 339: 365
28. Link to thalidomide's approved label: THALODMID (thalidomide) capsules. Washington (DC): US Food and Drug Administration/CTEP, 1998
29. Eriksson T, Björkman S, Roth B, et al. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 1995; 7: 44-52
30. Wnendt S, Finkam M, Winter W, et al. Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomideanalogues. Chirality 1996; 8: 390-6
31. Wnendt S, Zwingenberger K. Thalidomide's chirality. Nature 1997; 385: 303-4
32. Hague D, Smith RL. Enigmatic properties of (±)-thalidomide: an example of a stable racemic compound. Br J Clin Pharmacol 1988;26:623P
33. Günzler V, Hanauske-Abel HM, Tschank G, et al. Immunological effects of thalidomide: inactivity of the drug and several of its hydrolysis products in mononucleocyte proliferation tests. Arzneim-Forsch/Drug Res 1986; 36: 1138-41
34. Neubert R, Neubert D. Peculiarities and possible mode of actions of thalidomide. In: Kavlock RJ, Daston GP, editors. Drug toxicity in embryonic development. Handbook of Experimental Pharmacology. Heidelberg: Springer Verlag, 1996; 124:41-119
35. Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide. Focus on palliative care. Drugs 2000; 60: 273-92
36. Parman T, Wiley MJ, Wells PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 1999; 5: 582-5
37. Atra E, Sato El. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 1993: 11:487-93
38. Koransky W, Ullberg S. Autoradiographic investigations of 14C-labelled thalidomide and glutethimide in pregnant mice. Proc Soc Exp Biol Med 1964; 116: 512-6
39. Tanaka A, Hasegawa A, Urakubo G. Metabolic fate of thalidomide in rats. Chem Pharm Bull 1965; 13: 1263-5
40. MacKenzie RD, McGrath WR. Absorption of thalidomide in the rat. Proc Soc Exp Biol Med 1962; 109: 511-5
41. Schumacher H, Smith RL, Williams RT. The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol 1965; 25: 338-51
42. Teo SK, Evans MG, Brockman MJ, et al. Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs. ToxicolSci2001;59: 160-8
43. Maurice PD, Barkley AS, Alien BR. The effect of thalidomide on arachidonic acid metabolism in human polymorphonuclear leukocytes and platelets. Br J Dermatol 1986; 115: 677-80
44. Stephens TD, Bunde CJW, Fillmore BJ. Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 2000; 59: 1489-99
45. Tabin CJ. A developmental model for thalidomide defects. Nature 1998; 396: 322-3
46. Wells PG, Einn LM. Biochemical toxicology of chemical teratogenesis. Crit Rev Biochem Mol Biol 1996; 31: 1-40
47. Parman T, Chen G, Wells PG. Free radical intermediates of phenytoin and related teratogens. Prostaglandin H symhasecatalyzed bioactivation, electron paramagnetic resonance spectometry, and photochemical product analysis. J Biol Chem 1998; 273: 25079-88
48. Liu L, Wells PG. DNA oxidation as a potential molecular mechanism mediating drug-induced birth defects: phenytoin and structurally related teratogens initiate the formation of 8hydroxy-2′-deoxyguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues. Free Radie Biol Med 1995; 19: 639-48
49. Arlen RR, Wells PG. Extracellular thiol-disulfide status reflecting chemical toxicity mediated via oxidative stress: validation with paraquat and t-butylhydroperoxide, and implications for phenytoin and thalidomide teratogenicity. FASEB J 1990; 4: A608
50. Thiele A, Thormann M, Hofmann HJ, et al. A possible role of N-cadherin in thalidomide teratogenicity. Life Sei 2000; 67: 457-61
51. Guenzler V. Mechanisms of thalidomide teratogenicity. Nat Med 1999; 5: 853
52. McHugh SM, Rifkin IR, Deighton J, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Thl cytokine production in mitogenand antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995; 99: 160-7
53. Neubert R, Nogueira AC, Neubert D. Thalidomide derivatives and the immune system. I. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood. Arch Toxicol 1993; 67: 1-17
54. Neubert R, Nogueira AC, Neubert D. Thalidomide and the immune system. 2. Changes in receptors on blood cells of a healthy volunteer. Life Sei 1992; 51: 2107-16
55. Shannon EJ, Miranda RO, Morales MJ, et al. Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. Scand J Immunol 1981 ; 13 : 553-62
56. Shannon EJ, Truman RW, Christy SA, et al. Effect of thalidomide on induction of antibody synthesis in mice to the Tindependent antigen, DNP-Ficoll. Lepr Rev 1985; 56: 297-301
57. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699-703
58. Shannon EJ, Sandoval F. Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells. Immunopharmacol Immunotoxicol 1996; 18:59-72
59. McHugh SM, Rowland TL. Thalidomide and derivatives: immunological investigations of tumor necrosis factor-alpha (TNF-a) inhibition suggest drugs capable of selective gene regulation. Clin Exp Immunol 1997; 110: 151-4
60. Turk BE, Jiang H, Liu JO. Binding of thalidomide to alphalacid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sei USA 1996; 93: 7552-6
61. Moreira AL, Corral LG, Ye W, et al. Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Hum Retroviruses 1997; 13: 857-63
62. Helge T, Förster M, Neubert R. Influence of thalidomide and the derivative EM 12 on cytokine release by the monocytoid cell line mono MAC 6. Presented at the Spring Meeting of the German Society of Pharmacology; 1995
63. Makonkawkeyoon S, Limson-Pobre RN, Moreira AL, et al. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sei USA 1993; 90:5974-8
64. Peterson PK, Gekker G, Bornemann M, et al. Thalidomide inhibits lipoarabinomannan-induced upregulation of human immunodeficiency virus expression, Antimicrob Agents Chemother 1995; 39: 2807-9
65. Moreira AL, Wang J, Sarno EN, et al. Thalidomide protects mice against LPS-induced shock. Braz J Med Biol Res 1997: 30: 1199-207
66. Moller DR, Wysocka M, Greenlee BM, et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997; 159: 5157-61
67. Sampaio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologie manifestation of erythema nodosum leprosum. J Infect Dis 1993; 168: 408-14
68. Nogueira AC, Neubert R, Helge H, et al. Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sei 1994; 55: 77-92
69. Nogueira AC, Gräfe M, Neubert R. Effect of thalidomide and some derivatives on the adhesion of lymphocytes to endothelial cells. Naunyn-Schmiedebergs Arch Pharmacol 1995 ; 351 Suppl.: R130
70. Tramontana J, Utaipat U, Molloy A, et al. Thalidomide treatment reduces tumor necrosis factor-alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995; 1:384-97
71. Haslett PA, Corral LG, Albert M, et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+subset. J Exp Med 1998; 187: 1885-92
72. Meierhofer C, Dunzendorfer S, Wiedermann CJ. Protein kinase C-dependent effects on leukocyte migration of thalidomide. J Infect Dis 1999; 180:216-9
73. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996; 31:21321
74. Dunzendorfer S, Schratzberger P, Reinisch N, et al. Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine- and endotoxin-activated endothelium. Naunyn Schmiedebergs Arch Pharmacol 1997; 356: 529-35
75. Hastings RC, Morales MJ. The effect of thalidomide on neutrophil function. Int J Lepr other Mycobact Dis 1978; 46: 120
76. Fauré M, Lejeune JP, Gaucherand M, et al. PMN leukocytes chemotaxis: inhibition by thalidomide. Pathol Biol 1981 ; 29: 601-4
77. Miller JM, Ginsberg M, McElfatrick GC, et al. The anti-inflammatory effect and the analgetic property of thalidomide-268. Antibiot Med Clin Ther 1960; 7: 743-6
78. Dunzendorfer S, Herold M, Wiedermann CJ. Inducer-specific bidirectional regulation of endothelial interleukin-8 production by thalidomide. Immunopharmacology 1999; 43: 59-64
79. Davey PP, Ashrafian H. New therapies for heart failure: is thalidomide the answer? Q J Med 2000; 93: 305-11
80. Flier JS, Underhill LH. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334: 26
81. Roath S, Elves MW, Israels MCC. Effect of thalidomide on leucocyte cultures. Lancet 1962 20 Oct: 812-3
82. Roath S, Elves MW, Israels MC. Effects of thalidomide and its derivatives on human leucocytes cultured in vitro. Lancet 1963 2 Feb: 249-50
83. Gasparini C, Bersi M, Romito S. Effects of N-phthalyl-glutamic acid imide (thalidomide). II: Study of the cytostatic action on bone marrow cells and lymphocytes from peripheral blood in cultures. Arch Sei Med 1971; 128: 89-90
84. Lindahl-Kiessling K. Boeck JA. Effects of thalidomide on human leucocyte cultures. Lancet 1963 24 Aug: 405
85. Ogilvie JW, Kantor FS. The effect of thalidomide on the immune response. Fed Proc 1968; 27: 494
86. Schlegel PG, Fernandez LP, Baker J, el al. Thalidomide does not modulate the IL-2 response of activated Jurkat cells as measured by beta-gal-activity and by IL-2 production [abstract no. 43la]. Blood 1994; 84 Suppl. 10
87. Fernandez LP. Schlegel PG, Baker J, et al. Does thalidomide affect IL-2 response and production? Exp Hematol 1995; 23: 978-85
88. Shannon EJ, Sandoval F. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with concanavalin-A, staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology 1995; 31: 109-16
89. Östraat Ö, Riesbeck K, Qi Z, et al. Thalidomide prolonged graft survival in a rat cardiac transplant model but had no inhibitory effect on lymphocyte function in vitro. Transplant Immunol 1996; 4: 117-25
90. Shannon EJ, Sandoval F, Krahenbuhl JL. Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-alpha. Immunopharmacology 1997; 36: 9-15
91. Gad SM, Shannon EJ, Krotoski WA, et al. Thalidomide induces imbalances in T-lymphoeyte sub-populations in the circulating blood of healthy males. LeprRev 1985; 56: 35-9
92. Shannon EJ. Ejigu M, Haile-Mariam HS, et al. Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. Lepr Rev 1992;63:5-11
93. Arala-Chaves M, Vilanova M, Ribeiro A, et al. Immunostimulatory effect of thalidomide in normal C57BL/6 mice is compatible with stimulation of a highly connected central immune system. Scand J Immunol 1994; 40: 535-42
94. Wemambu SN, Turk JL, Waters MF, et al. Erythema nodosum leprosum: a clinical manifestation of the Arthus phenomenon. Lancet 1969 1 Nov; 2: 933-5
95. Miranda RO, Morales MJ, Hastings RC. Thalidomide's effect on antibody formation. Fed Proc 1977; 1231
96. Shannon EJ, Miranda RO, Hastings RC. The effect of thalidomide on de novo antibody synthesis. Int J Lepr Other MycobactDis 1979:47: 381
97. Doll NJ, Barnhill RL, Hastings RC, et al. Thalidomide induced alteration of human peripheral blood monocyte activity. Clin Res 1983;31:920A
98. Jenkins JS, Powell RJ, Allen BR. Investigation of the effect of thalidomide and dapsone on the respiratory burst of normal leukocytes. In: Lehner T, Barnes CG, editors. Recent advances in Behçet's disease. London: Royal Society of Medicine Services, 1986:373-8
99. Goihman-Yahr M, Convit J, Rodrîguez-Ochoa G, et al. Significance of neutrophil activation in reactional lepromatous leprosy: effects of thalidomide in vivo and in vitro. Activation in adjuvant diseases. Int Arch Allergy Appl Immunol 1978; 57: 317-32
100. Nielsen H, Valerius NH. Thalidomide enhances Superoxide anion release from human polymorphonuclear and mononuclear leukocytes. Acta Pathol Microbiol Immunol Scand Sect C Immunol 1986; 94: 233-7
101. Williams KM, Ye W, Lohrer F, et al. Effect of thalidomide on polymorphonuclear leukocyte function. Presented at the Annual Meeting of the Australian Rheumatism Association; 1991 Dec; Perth, Australia
102. Londono F. Thalidomide in the treatment of actinic prurigo. Int JDermatol 1973; 12: 326-8
103. Ochonisky S, Revuz J. Thalidomide use in dermatology. Eur J Dermatol 1994:4:9-15
104. Charue D, Chauvin E, Duguet C, et al. Thalidomide decreases the production of GM-CSF and TNFa in mixed epidermal cell lymphocyte reaction. J Invest Dermatol 1995; 105: 479
105. Barkley ASJ, Bather PC, Allen BR. Retinoids enhance monocyte/endothelium interaction. J Invest Dermatol 1987; 89: 320
106. McCarty MF. Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. Med Hypotheses 1997; 49: 123-31
107. Peterson PK. Hu S. Sheng WS, et al. Thalidomide inhibits tumor necrosis factor-alpha production by lipopolysaccharideand lipoarabinomannan-stimulated human microglial cells. J Infect Dis 1995; 172: 1137-40
108. Meunier L, Marck Y, Ribeyre C, et al. Adult cutaneous Langerhans cell histiocytosis: remission with thalidomide treatment. Br J Dermatol 1995; 132: 168
109. Karrow N A, McCay JA, Brown RD, et al. Thalidomide stimulates splenic IgM antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3FI mice. Toxicol Appl Pharmacol 2000; 165: 237-44
110. Oliver SJ. The thl/th2 paradigm in the pathogenesis of scleroderma, and its modulation by thalidomide. Curr Rheumatol Rep 2000; 2: 486-91
111. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Syndr Hum Retrovirol 1996; 11: 247-57
112. Shannon EJ, McLean K. Howe RC, et al. Thalidomide does not affect selected immunomodulating surface receptor molecules on cells with immune potential. Int J Lepr Other Mycobact Dis 1993; 61 Suppl. 4: 105A
113. Förster M, Neubert R. Lack of effects on fetal thymus and lymphocyte development in marmoset fetuses and newborns following treatment with thalidomide. Teratology 1995; 51: 23A-4A
114. NishimuraK, HashimotoY, Iwasaki S.Enhancement of phorbol ester-induced production of tumor necrosis factor alpha by thalidomide. Biochem Biophys Res Commun 1994; 199: 455-60
115. Nishimura K, Hashimoto Y, Iwasaki S. (S)-form of alphamethyI-N(alpha)-phthaiimido-glutarimide, but not its (R)form, enhanced phorbol ester-induced tumor necrosis factor-alpha production by human leukemia cell HL-60: implication of optical resolution of thalidomidal effects. Chem PharmBull 1994; 42: 1157-9
116. Sasakt K. Shibata Y, Nishimura K, et al. Enhancement of 12-Otetradecanoylphorbol-13-acetate-induced tumor necrosis factor alpha production by phenethylphthalimide analogs. Biol PharmBull 1994; 17: 1313-5
117. Shibata Y, Shichita M, Sasaki K, et al. N-alkylphthalimides: structural requirement of thalidomidal action on 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor alpha production by human leukemia HL-60 cells. Chem PharmBull 1995; 43: 177-9
118. Sampaio EP, Moreira AL, Sarno EN, et al. Prolonged treatment with recombinant Interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992; 175: 1729-37
119. Barnes PF, Chatterjee D, Brennan PJ, et al. Tumor necrosis factor production in patients with leprosy. Infect Immun 1992:60: 1441-6
120. Ching LM, Xu ZF, Gummer BH, et al. Effect of thalidomide on tumor necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1995;72: 339-43
121. Schneider J, Wnendt S, Korioth J, et al. Thalidomide inhibits superantigen-induced TNF-alpha release in mice. 12th European Immunology Meeting of the European Federation of Immunologie Societies; 1994 Jun 14-17; Barcelona, Spain
122. Netea MG, Blok WL, Kullberg BJ, et al. Pharmacologie inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice. J Infect Dis 1995; 171: 393-9
123. Shannon EJ, Morales MJ, Sandoval F. Immunomodulatory assays to study structure-activity relationships of thalidomide. Immunopharmacology 1997; 35: 203-12
124. Chuong PH, Galons H, Voisin J, et al. In vitro and in vivo immunosuppressive potential of thalidomide and its derivative, N-hydroxythalidomide, alone and in combination with cyclosporin A. Int J Immunopharmacol 1997; 19: 289-96
125. Weglicki WB, Stafford RE, Dickens BF, et al. Inhibition of tumor necrosis factor-alpha by thalidomide in magnesium deficiency. Mol Cell Biochem 1993; 129: 195-200
126. Tavares JL, Wangoo A, Dilworth P, et al. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir Med 1997; 91:31-9
127. Miyachi H, Azuma A, Hioki E, et al. Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production. Biochem Biophys Res Commun 1996; 224: 426-30
128. Azuma A, Miyachi H, Shibata Y, et al. Augmentation by phthalimides of phorbol ester-induced expression of tumor necrosis factor alpha message. Biol Pharm Bull 1996; 19: 1001-3
129. Ishikawa M, Kanno S, Takayanagi M, et al. Thalidomide promotes the release of tumor necrosis factor-alpha (TNF-alpha) and lethality by lipopolysaccharide in mice. Biol Pharm Bull 1998:21:638-40
130. Rowland TL, McHugh SM, Deighton J, et al. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology 1998; 40: 11-20
131. Moreira AL. Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 167580
132. Jasinski M, Wieckiewicz J, Ruggiero I, et al. Isotype-specific regulation of MHC class II gene expression in human monocytes by exogenous and endogenous tumor necrosis factor. J Clinlmmunol 1995; 15: 185-93
133. Walchner M, Messer G, Wierenga EA, et al. Reconstitution of transcription factor binding to the conserved lymphokine element-0 and downregulation of NF-kappaB activity after thalidomide treatment of systemic lupus erythematosus. Presented at the 22nd Annual Meeting of the Arbeitsgemeinschaft Dermatologischer Forschung; 1994 Nov; Würzburg, Germany
134. Huang PH, McBride WG, Tuman WG. Interaction of thalidomide with DNA of rabbit embryos: a possible explanation for its immunosuppressant and teratogenic effects. Pharmacol Toxicol 1999; 85: 103-4
135. Arthus M. Repeated injections of equine serum in the rabbit. C R Seances Soc Biol Ses Fil 1903; 55: 817-20
136. Ulrich M, Salas de B, Convit J. Thalidomide activity in experimental Arthus and anaphylactic reactions. Int J Lepr Other MycobactDis 1971; 39: 131-5
137. Pflum LR, Graeme ML. The Arthus reaction in rats, a possible test for anti-inflammatory and antirheumatic drugs. Agents Actions 1979; 9: 184-9
138. Crain E, Mclntosh KR, Gordon G, et al. The effect of thalidomide on experimental autoimmune myasthenia gravis. J Autoimmun 1989; 2: 197-202
139. Jorizzo JL, Schmalstieg FC, Solomon AR, et al. Thalidomide effects in Behçet's syndrome and pustular vasculitis. Arch Intern Med 1986; 146: 878-81
140. Pfordte K. Über die Beeinflussung des Serumproperidinsystems durch verschiedene Arzneimittel. 1. Mitteilung : Antibiotica, Chemotherapeutica, Antidiabetica, Hypnotica, Immunosuppressiva und Antihyperthyreotica. Pharmazie 1971:26:301-2
141. Hastings RC, Morales MJ. Studies of the mechanism of the action of thalidomide in leprosy. Int J Lepr Other Mycobact Dis 1973:41:494
142. Schneider J, Bruckmann W, Zwingenberger K. Extravasation of leukocytes assessed by intravital microscopy: effect of thalidomide. Inflamm Res 1997; 46: 392-7
143. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sei USA 1994; 91: 4082-5
144. Minchinton AI, Fryer KH, Wendt KR, et al. The effect of thalidomide on experimental tumors and métastases. Anticancer Drugs 1996:7:339-43
145. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularisation. Exp Eye Res 1997; 64: 971-8
146. Kruse FE, Joussen AM. Rohrschneider K, et al. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 1998; 236: 461-6
147. D'Amato RJ. Studies examining the effects of thalidomide on angiogenesis. Presented at the 1BC Conference; 1995 Dec
148. Gutman M, Szold A, Ravid A, et al. Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Res 1996; 16: 3673-7
149. Mihich E, Fefer A. Biological response modifiers: subcommittee report. NCI Monogr 1983; 63
150. Neubert R, Helge H, Neubert D. Thalidomide and the immune system. 4. Down-regulating of the CD26 receptor, probably involved in the binding of HIV components to T cells in primates. Life Sei 1995; 56: 407-20
151. Haslett PA, Klausner JD, Makonkawkeyoon S, et al. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses 1999; 15: 1169-79
152. Playfair JH, Leuchars E. Davies AJ. Effect of thalidomide on skin-graft survival. Lancet 1963 4 May: 1003-4
153. Bore PJ, Scothorne RJ. Effect of thalidomide on survival of skin homografts in rabbits. Lancet 1966 4 Jun; 1: 1240-1
154. Jaffe WP. Failure of thalidomide to influence homograft immunity in chickens. Vet Rec 1966; 78: 883-4
155. Hellman K. Hemmung der Immunisierungsreaktion durch Thalidomid und die Folgen dieses Vorganges für die Theorie der teratogenen Wirkung dieser Substanz. Wiener Med Wochenschrift 1967; 15:415-8
156. EllenriederM, Frankus E, Krüpe W. Immunosuppression durch cyclische Imide bei der Ratte. Klinische Wochenschrift 1967; 45(22): 1159-60
157. Groenewald JH, Weber HW. DeKlerk JN, el al. Methods of chemical immunosuppressive treatment in baboon and rhesus monkey allotransplants. Medical Primatology 1970. Proceedings of the 2nd Conference on Experimental Medicine and Surgery in Primates; 1969; New York. Basel: Karger, 1971: 130-8
158. Murphy GP, Mirand EA, Groenewald JH, et al. Erythropoietin release in renal allografted baboons, with and without immunosuppression. Invest Urol 1970; 7: 271-82
159. Murphy GP, Brede HD, Weber HW, et al. Thalidomide immunosuppression in canine renal allotransplantation. J Med 1970; 1:66-73
160. Uthoff K, Zehr KJ, Gaudin PB, el al. Thalidomide as replacement for steroids in immunosuppression after lung transplantation. Ann Thorac Surg 1995; 59: 277-82
161. Emre S, Sumrani N, Hong S. Beneficial effect of thalidomide and ciclosporin combination in heterotopic cardiac transplantation in rats. Eur Surg Res 1990; 22: 336-9
162. Tamura F, Vogelsang GB, Reitz BA, et al. Combination of thalidomide and cyclosporine for cardiac allograft rejection. Comparison with combination methylprednisolone and cyclosporine. Transplantation 1990; 49: 20-5
163. Östraat Ö, Ekberg H, Schatz H, et al. Thalidomide prolongs graft survival in rat cardiac transplants. Transplant Proc 1992; 24: 2624-5
164. Vogelsang GB, Hess AD, Santos GW. Thalidomide for treatment of graft-versus-host disease. Bone Marrow Transplant 1988:3:393-8
165. Vogelsang GB, Hess AD, Friedman KJ, et al. Therapy of chronic graft-v-host disease in a rat model. Blood 1989; 74: 507-11
166. Vogelsang GB, Wells MC, Santos GW, et al. Combination lowdose thalidomide and cyclosporine prophylaxis for acule graft-versus-host disease in a rat mismatched model. Transplant Proc 1988; 20 (2 Suppl. 2): 226-8
167. Mehta P, Kedar A, Graham-Pole J, et al. Thalidomide in children undergoing bone marrow transplantation: series at single institution and review of the literature. Pediatrics 1999;103:e44
168. Forsyth CJ, Cremer PD, Torzillo P, et al. Thalidomide responsive chronic pulmonary GVHD. Bone Marrow Transplant 1996; 17:291-3
169. Chao NJ, Parker PM, Niland JC, et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol Blood Marrow Transplant 1996; 2: 86-92
170. Cole CH, Rogers PC, Pritchard S, et al. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation. Bone Marrow Transplant 1994; 14: 937-42
171. Rovelli A, Arrigo C, Nesi F, et al. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplant 1998; 21: 577-81
172. Urata K, Brault A, Rocheleau B, et al. Role of Kupffer cells in the survival after rat liver transplantation with long portal vein clamping times. Transplant Int 2000; 13: 420-7
173. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992; 326: 1055-8
174. Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995; 86: 3604-9
175. Fife K, Howard MR, Gracie F, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 1998:9:751-5
176. Ravot E, Lisziewicz J, Lori F. New uses for old drugs in HIV infection. Drugs 1999; 58: 953-63
177. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group [see comments]. N Engl J Med 1997; 336: 1487-93
178. Munshi NC, Barlogie B, Desikan KR, et al. Novel approaches in myeloma therapy. Semin Oncol 1999; 26: 28-34
179. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-71
180. Postema PT, den Haan P, van Hagen PM, et al. Treatment of colitis in Behcet's disease with thalidomide. Eur J Gastroenterol Hepatol 1996; 8: 929-31
181. Wettstein AR, Meagher AP. Thalidomide in Crohn's disease. Lancet 1997; 350: 1445-6
182. Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999; 117: 1271-7
183. Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. Gastroenterology 1999; 117: 1278-87
184. Carlesimo M, Giustini S, Rossi A, et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32: 866-9
185. Vitali C, Doria A, Tincani A, et al. International survey on the management of patients with SLE. I. General data on the participating centers and the results of a questionnaire regard-ing mucocutaneous involvement. Clin Exp Rheumatol 1996; 14Suppl. 16:817-22
186. Strand V. Biologic agents and innovative interventional approaches in the management of systemic lupus erythematosus. CurrOpin Rheumatol 1999; 11: 330-40
187. Duong DJ, Spigel GT, Moxley III RT, et al. American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol 1999; 135: 1079-87
188. Werth VP, Dutz JP, Sontheimer RD. Pathogenetic mechanisms and treatment of cutaneous lupus erythematosus. Curr Opin Rheumatol 1997; 9: 400-9
189. Sato El, Assis LS, Lourenzi VP, et al. Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus. Rev Assoc Bras 1998; 44: 289-93
190. Powell RJ, Alien BR, Jenkins JS, et al. Investigation and treatment of
191. Schuler U, Ehninger G. Thalidomide: rationale for renewed use in immunological disorders. Drug Saf 1995; 12: 364-9